Prostate Cancer

A third data cut-off reassessment by the German Institute for Quality and Efficiency in Health Care found enzalutamide provided an added benefit for patients with high-risk non-metastatic castration-resistant prostate cancer.

After adjustments for a number of clinical factors and factors related to access to care, the overall survival disparity among men undergoing radical prostatectomy was significantly decreased, but not eliminated, for Black men.

A study published in the Journal of Clinical Oncology found that rucaparib can successfully treat patients with metastatic castration-resistant prostate cancer who have mutated BRCA/BRCA2 genes.

A study found that delaying radiation therapy while remaining on hormone therapy for patients with unfavorable intermediate-risk or high-risk localized prostate cancer to avoid potential exposure to COVID-19 did not negatively impact overall survival.

Among men with advanced prostate cancer, relugolix did not achieve statistical superiority for castration resistance-free survival compared to leuprolide acetate in men with metastatic disease through 48 weeks.

The ATR inhibitor BAY 1895344 appeared promising in patients with a range of advanced, heavily pre-treated cancers in a dose-escalation portion of a phase 1 clinical trial.

TLX591-CDx (illumet) is a radiopharmaceutical targeting prostate-specific membrane antigen intended for the imaging of prostate cancer using positron emission tomography.

Treatment with a novel BiTE® immuno-oncology therapy showed a manageable safety profile with preliminary efficacy in patients with metastatic castration-resistant prostate cancer.

In patients with metastatic castration-resistant prostate cancer (mCRPC) with PTEN loss, ipatasertib combined with abiraterone acetate (Zytiga) plus prednisone led to a significantly superior radiographic progression-free survival and antitumor activity.

The PARP inhibitor reduced the risk for death by 31% in men with metastatic castration-resistant prostate cancer, compared with enzalutamide or abiraterone plus prednisone.

The study evaluated the use of darolutamide in men with nonmetastatic, castration-resistant prostate cancer compared with placebo while they continued to receive androgen-deprivation therapy.

Researchers indicated that these early data support the rationale for further evaluation of immune-checkpoint inhibitor-based combinations in patients with metastatic castration resistant prostate cancer.

This study found focal high intensity focused ultrasound ablation of the prostate to be safe and provide excellent potency, continence preservation, and adequate short-term prostate cancer control.

A phase 1b/2a study of the combination in patients with metastatic castration resistant prostate cancer demonstrated acceptable tolerability and potential efficacy.

CancerNetwork® spoke with Ahmet Murat Aydin, MD, about a study designed to evaluate bipolar radiofrequency ablation.

Researchers indicated that “these results reinforce the idea that there can be biological differences in prostate cancers between different ancestral groups.”

The findings supported the accelerated approval of rucaparib for the treatment of men with metastatic castration-resistant prostate cancer who have a deleterious BRCA mutation and who have previously received androgen receptor-directed therapy and taxane-based chemotherapy.

This study found that implementation of the enhanced recovery after surgery pathway combined with prehabilitation programs can significantly change the postoperative course of patients.

In this study, investigators found that the hydrogel spacer has a favorable risk-benefit profile for patients receiving radiotherapy for prostate cancer.

This data may help to inform future recommendations for surveillance of BRCA1/2-associated cancers, according to researchers.

In this study, researchers observed no association between black race and the risk of SREs and overall mortality in men with bone metastatic castration-resistant prostate cancer.

The study met its co-primary endpoint of radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer and whose tumors had PTEN loss.

Researchers detailed methods and processes that may be useful for additional research and validation of computational hematoxylin and eosin staining deep learning models and the images generated by them.

Payment models with shared-savings components, such as the Oncology Care Model, may be associated with fewer visits and lower costs in certain cancer settings in the first year.

This study found that regional- and distant-stage prostate cancer incidence continues to increase in US men aged ≥50 years.